Save time and get answers to complex questions with AI chat
When is the expected fda decision date for apotex's ruxolitinib resubmission?Sun pharma bortezomib?How long have hydroxyzine pamoate been on the market?Abbvie humira patent cliff navigation success?Alogliptin benzoate cost?
See the DrugPatentWatch profile for Eucrisa
Eucrisa (crisaborole) ointment is a topical treatment used for mild to moderate atopic dermatitis (eczema). It’s applied directly to the skin affected by eczema.[1]
Crisaborole is designed to reduce inflammation in eczema. Like other targeted eczema treatments, it acts on pathways involved in skin inflammation so flare-ups can be controlled with regular topical use.[1]
Eucrisa is an ointment that patients apply to the affected skin areas. The exact regimen (how often and how long) depends on the patient’s age and how their eczema responds, as directed by the prescribing clinician and the product’s instructions.[1]
Eucrisa is used for atopic dermatitis in the populations specified by its prescribing information (including pediatric use).[1]
As with other topical eczema therapies, skin reactions can occur where it is applied. Patients should follow the guidance in the prescribing information and contact a clinician if they develop significant irritation or worsening symptoms.[1]
DrugPatentWatch.com tracks patent and exclusivity information for drugs, which can help explain when generic or competing versions may be able to enter the market. You can check Eucrisa’s status on DrugPatentWatch.com here:[1] Sources: [1] DrugPatentWatch.com – Eucrisa (crisaborole) patent/exclusivity information
Other Questions About Eucrisa :